Abeona Focuses on Infrastructure for $3.1M Rare-Disease Therapy

Abeona Therapeutics is prioritizing long-term infrastructure and patient access instead of rapid initial revenue growth for its rare-disease therapy, ZEVASKYN. The company is navigating complex manufacturing and reimbursement hurdles while scaling its operational capacity to meet the demands of a $3.1 million treatment cycle. It has opted for a measured rollout strategy.

"The appeal of the therapy lies in durable wound healing and pain reduction, which may reduce the burden of daily dressing changes and improve quality of life," said Vish Seshadri, CEO of Abeona, at the Cantor healthcare conference.

Current Commercial Footprint

As of the most recent update, Abeona has treated approximately 12 patients with ZEVASKYN. The company currently supports these treatments through seven active, qualified treatment centers. Management stated that the current phase focuses on establishing the support systems needed to handle the logistical requirements of the therapy.

"The company is still building the foundation needed for a larger commercial rollout," said Madhav Vasanthavada, Chief Commercial Officer at Abeona.

Scaling Manufacturing and Reimbursement

Although the current reach is limited, the firm has outlined a plan to expand its production capabilities over several years. Abeona is targeting an increase from its current capacity of six manufacturing slots per month to 10 slots per month by 2027. This ramp-up aligns with the company’s long-term infrastructure goals instead of an immediate, high-volume launch.

Despite the $3.1 million price point per treatment cycle, the company reports progress in securing payer support. According to a conference transcript, Abeona has secured coverage for over 95% of commercial lives and has established baseline Medicaid coverage across all 51 U.S. jurisdictions.

What Is at Stake

For rare-disease drug developers, the transition from clinical trial success to commercial viability depends on the ability to navigate reimbursement hurdles and complex delivery chains. By securing broad insurance coverage early, Abeona aims to mitigate the financial barriers associated with high-cost gene therapies. The company continues to focus on maintaining the quality of the treatment process while slowly expanding the number of centers capable of administering the therapy.